Skip to main content
. 2024 Oct 17;16:17588359241290718. doi: 10.1177/17588359241290718

Figure 2.

Figure 2.

The PFS of patients received (a) first-line platinum-pemetrexed combined with bevacizumab RP or its biosimilar and (b) first-line EGFR-TKIs combined with bevacizumab RP or its biosimilar.

BB, bevacizumab biosimilar; CT, chemotherapy; EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor; PFS, progression-free survival; RP, reference product.